Copertina

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Takao Miwa, Luis Antonio Díaz, Aenne Harberts, Yoshimi Yukawa‐Muto, Tomohiro Nakamura, Xinlian Zhang, Rohit Loomba, Bernd Schnabl
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
di: Donghee Kim, et al.
Pubblicazione: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
di: Maral Amangurbanova, et al.
Pubblicazione: (2024)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
di: Jee‐Fu Huang, et al.
Pubblicazione: (2026)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
di: Luis Antonio Díaz, et al.
Pubblicazione: (2025)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
di: Luis Antonio Díaz, et al.
Pubblicazione: (2025)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Soroor Owrangi, et al.
Pubblicazione: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
di: Karen Cheuk‐Ying Ho, et al.
Pubblicazione: (2025)

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
di: Donghee Kim, et al.
Pubblicazione: (2025)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
di: Kelly Torosian, et al.
Pubblicazione: (2025)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
di: Rosellina M. Mancina, et al.
Pubblicazione: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
di: Yee Hui Yeo, et al.
Pubblicazione: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
di: Donghee Kim, et al.
Pubblicazione: (2025)

A Message From the Editors
di: Colin W. Howden, et al.
Pubblicazione: (2024)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Stergios A. Polyzos, et al.
Pubblicazione: (2024)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
di: Kaleb Tesfai, et al.
Pubblicazione: (2026)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
di: Chunlong Liu, et al.
Pubblicazione: (2025)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
di: Stine Johansen, et al.
Pubblicazione: (2026)

Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States
di: Sheila L. Noon, et al.
Pubblicazione: (2025)

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
di: Julia Karady, et al.
Pubblicazione: (2024)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Gian Paolo Caviglia, et al.
Pubblicazione: (2025)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
di: Selena Z. Kuo, et al.
Pubblicazione: (2025)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Zhanbo Qu
Pubblicazione: (2026)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
di: Luis Calzadilla Bertot, et al.
Pubblicazione: (2025)

Steatotic Liver Disease Prevalence in China: A Population‐Based Study and Meta‐Analysis of 17.4 Million Individuals
di: Zhenqiu Liu, et al.
Pubblicazione: (2025)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
di: Takao Miwa, et al.
Pubblicazione: (2026)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria
di: Julie Bonn, et al.
Pubblicazione: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
di: Amy Sangam, et al.
Pubblicazione: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
di: Samer Gawrieh, et al.
Pubblicazione: (2024)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
di: Na Tian, et al.
Pubblicazione: (2025)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
di: Maryam Zafer, et al.
Pubblicazione: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Shinya Yokoyama, et al.
Pubblicazione: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
di: C. C. Mark Cheah, et al.
Pubblicazione: (2025)

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
di: Zhe‐Kun Xiong, et al.
Pubblicazione: (2025)